D. Boral Capital, a premier investment bank focused on high-quality mid-market and growth issuers, has concluded an outstanding year in 2024, solidifying its position as a leader in the financial services industry. The firm’s impressive performance is reflected in its comprehensive transaction portfolio, showcasing its expertise across various sectors and transaction types.
In 2024, D. Boral Capital achieved remarkable milestones:
– Completed 65 transactions
– Advised on approximately $8.69 billion in aggregate transaction value
– Ranked #1 in SPAC IPOs in terms of deal volume
The firm’s team demonstrated excellence across various roles, including Sole Book-runner, Exclusive Placement Agent, and Financial Advisor. This versatility underscores D. Boral Capital’s ability to provide tailored solutions to meet diverse client needs.
Notable achievements in 2024 include:
– Projecting revenues of approximately $100 million
– Achieving an unaudited net income of around $25 million
– Maintaining a strong balance sheet with no debt
– Ranking number one worldwide in Regular way and SPAC IPOs since 2022 for number of new issues
D. Boral Capital’s success is further evidenced by its role in significant transactions, such as:
– Acting as exclusive placement agent for Webuy Global Ltd’s $3.7 million registered direct offering
– Serving as co-manager for ImmunityBio, Inc.’s $100 million underwritten public offering
– Facilitating FibroBiologics, Inc.’s $25 million financing as exclusive placement agent
As D. Boral Capital looks ahead to 2025, the firm expresses gratitude to its clients, partners, and dedicated team for contributing to an exceptional year. With a strong foundation and proven track record, D. Boral Capital is well-positioned for continued success and growth in the coming year.